Paul E. Verweij

49.0k total citations · 7 hit papers
498 papers, 25.2k citations indexed

About

Paul E. Verweij is a scholar working on Infectious Diseases, Epidemiology and Cell Biology. According to data from OpenAlex, Paul E. Verweij has authored 498 papers receiving a total of 25.2k indexed citations (citations by other indexed papers that have themselves been cited), including 393 papers in Infectious Diseases, 260 papers in Epidemiology and 99 papers in Cell Biology. Recurrent topics in Paul E. Verweij's work include Antifungal resistance and susceptibility (383 papers), Fungal Infections and Studies (224 papers) and Plant Pathogens and Fungal Diseases (98 papers). Paul E. Verweij is often cited by papers focused on Antifungal resistance and susceptibility (383 papers), Fungal Infections and Studies (224 papers) and Plant Pathogens and Fungal Diseases (98 papers). Paul E. Verweij collaborates with scholars based in Netherlands, United States and United Kingdom. Paul E. Verweij's co-authors include Willem J. G. Melchers, Jacques F. Meis, Johan W. Mouton, Eveline Snelders, J. Peter Donnelly, Adilia Warris, Joseph Meletiadis, Roger J. M. Brüggemann, Monique A. S. H. Mennink‐Kersten and Antonius J. M. M. Rijs and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Paul E. Verweij

486 papers receiving 24.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tackling the emerging threat of antifungal resistance to human health

2022 675 citations Roger J. M. Brüggemann, Adilia Warris et al. profile →
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism

2008 568 citations Eveline Snelders, Robert A. Samson et al. profile →
EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

2008 549 citations J. L. Rodríguez-Tudela, Francesco Barchiesi et al. profile →
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?

2009 464 citations Paul E. Verweij, Eveline Snelders et al. profile →
Azole Resistance in Aspergillus fumigatus : Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?

2015 434 citations Paul E. Verweij, Willem J. G. Melchers et al. profile →
Clinical Implications of Azole Resistance inAspergillus fumigatus, the Netherlands, 2007–2009

2011 362 citations Eveline Snelders, Bart Rijnders et al. profile →
Invasive candidiasis: current clinical challenges and unmet needs in adult populations

2023 75 citations Paul E. Verweij et al. Journal of Antimicrobial Chemotherapy profile →

Peers

Countries citing papers authored by Paul E. Verweij

Since Specialization

Citations

This map shows the geographic impact of Paul E. Verweij's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Verweij with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Verweij more than expected).

Fields of papers citing papers by Paul E. Verweij

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul E. Verweij. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Verweij. The network helps show where Paul E. Verweij may publish in the future.

Co-authorship network of co-authors of Paul E. Verweij

This figure shows the co-authorship network connecting the top 25 collaborators of Paul E. Verweij. A scholar is included among the top collaborators of Paul E. Verweij based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul E. Verweij. Paul E. Verweij is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genetic mutations in Cryptococcus neoformans pyrimidine salvage pathway enzymes contribute to reduced susceptibility against 5-fluorocytosine 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Alfredo Cabrera‐Orefice, Jordy P. M. Coolen, Abdullah M. S. Al‐Hatmi, Sarah Ahmed, Willem J. G. Melchers, Yun C. Chang, Kyung J. Kwon‐Chung, Sybren de Hoog, Paul E. Verweij, Jochem B. Buil	1
2	Evolutionary trends in antifungal resistance: a meta-analysis 2024 ·Microbiology Spectrum ·(unknown), Abdullah M. S. Al‐Hatmi, Roxana G. Vitale, Michaela Lackner, Sarah Ahmed, Paul E. Verweij, Yingqian Kang, Sybren de Hoog	7
3	Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study 2024 ·Journal of Antimicrobial Chemotherapy ·(unknown), (unknown), Joost Wauters, Yves Debaveye, Bart Rijnders, Paul E. Verweij, Roger J. M. Brüggemann, Isabel Spriet, Erwin Dreesen	0
4	Retrospective Multicenter Evaluation of the VirClia Galactomannan Antigen Assay for the Diagnosis of Pulmonary Aspergillosis with Bronchoalveolar Lavage Fluid Samples from Patients with Hematological Disease 2023 ·Journal of Clinical Microbiology ·Jochem B. Buil, (unknown), Albert Dunbar, Alexander Schauwvlieghe, Marijke Reynders, (unknown), Karin van Dijk, Anke H. W. Bruns, Pieter‐Jan Haas, Douwe F. Postma, Bart J. Biemond, (unknown), Elizabeth de Kort, Willem J. G. Melchers, Paul E. Verweij, Bart Rijnders	15
5	Regional Impact of COVID-19-Associated Pulmonary Aspergillosis (CAPA) during the First Wave 2022 ·Journal of Fungi ·Robbert G. Bentvelsen, Andreas van Arkel, Tom A. Rijpstra, (unknown), Simone van der Sar–van der Brugge, Daan W. Loth, Peter van Wijngaarden, (unknown), (unknown), B. M. W. Diederen, Peter C. Wever, Alexander C. A. P. Leenders, (unknown), (unknown), Wouter van den Bijllaardt, Paul E. Verweij	9
6	Azole-Resistance Development; How the Aspergillus fumigatus Lifecycle Defines the Potential for Adaptation 2021 ·Journal of Fungi ·Jianhua Zhang, Alfons J. M. Debets, Paul E. Verweij, Eveline Snelders	12
7	Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension 2020 ·Hypertension ·Paul E. Verweij, Parisa Danaietash, Bruno Flamion, Joël Ménard, M Bellet	59
8	Suboptimal Dosing of Fluconazole in Critically Ill Patients: Time To Rethink Dosing 2020 ·Antimicrobial Agents and Chemotherapy ·Eline W. Muilwijk, Dylan W. de Lange, Jeroen Schouten, Roeland E. Wasmann, Rob ter Heine, David M. Burger, Angela Colbers, P. J. A. Haas, Paul E. Verweij, Peter Pickkers, Roger J. M. Brüggemann	22
9	In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates 2020 ·Journal of Antimicrobial Chemotherapy ·Jochem B. Buil, Roger J. M. Brüggemann, Laura Bedin Denardi, Willem J. G. Melchers, Paul E. Verweij	7
10	Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays 2016 ·Journal of Clinical Microbiology ·Elham Salehi, Mohammad Taghi Hedayati, Jan Zoll, Haleh Rafati, Maryam Ghasemi, (unknown), Mahdi Abastabar, (unknown), Eveline Snelders, Henrich A. van der Lee, Antonius J. M. M. Rijs, Paul E. Verweij, Seyedmojtaba Seyedmousavi, Willem J. G. Melchers	63
11	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model 2014 ·Journal of Antimicrobial Chemotherapy ·Maria Siopi, Eleftheria Mavridou, Johan W. Mouton, Paul E. Verweij, Loukia Zerva, Joseph Meletiadis	28
12	Susceptibility Breakpoints for Amphotericin B and Aspergillus Species in an In Vitro Pharmacokinetic-Pharmacodynamic Model Simulating Free-Drug Concentrations in Human Serum 2014 ·Antimicrobial Agents and Chemotherapy ·(unknown), Johan W. Mouton, Paul E. Verweij, Loukia Zerva, Joseph Meletiadis	16
13	Pharmacodynamics and Dose-Response Relationships of Liposomal Amphotericin B against Different Azole-Resistant Aspergillus fumigatus Isolates in a Murine Model of Disseminated Aspergillosis 2013 ·Antimicrobial Agents and Chemotherapy ·Seyedmojtaba Seyedmousavi, Willem J. G. Melchers, Johan W. Mouton, Paul E. Verweij	34
14	Identification of Paecilomyces variotii in Clinical Samples and Settings 2010 ·Journal of Clinical Microbiology ·Jos Houbraken, Paul E. Verweij, (unknown), Andrew M. Borman, Robert A. Samson	87
15	Drosomycin-Like Defensin, a Human Homologue of Drosophila melanogaster Drosomycin with Antifungal Activity 2008 ·Antimicrobial Agents and Chemotherapy ·Anna Simon, Bart Jan Kullberg, Brian Tripet, Otto C. Boerman, Patrick L.J.M. Zeeuwen, Johanna van der Ven‐Jongekrijg, Paul E. Verweij, Joost Schalkwijk, Robert S. Hodges, Jos W.M. van der Meer, Mihai G. Netea	40
16	Improved Detection of Circulating Aspergillus Antigen by Use of a Modified Pretreatment Procedure 2008 ·Journal of Clinical Microbiology ·Monique A. S. H. Mennink‐Kersten, Dorien Ruegebrink, Rocus R. Klont, Adilia Warris, Nicole M. A. Blijlevens, J. Peter Donnelly, Paul E. Verweij	16
17	Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach 2007 ·Journal of Antimicrobial Chemotherapy ·André J.H.A. Ament, (unknown), Paul E. Verweij, Ronald de Groot, Adilia Warris, J. Peter Donnelly, (unknown), Johan L. Severens	14
18	International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole 2005 ·Journal of Clinical Microbiology ·Ana Espinel‐Ingroff, Francesco Barchiesi, Manuel Cuenca‐Estrella, Michael A. Pfaller, Michael G. Rinaldi, J. L. Rodríguez-Tudela, Paul E. Verweij	118
19	In Vitro Interactions between Amphotericin B, Itraconazole, and Flucytosine against 21 Clinical Aspergillus Isolates Determined by Two Drug Interaction Models 2004 ·Antimicrobial Agents and Chemotherapy ·D. T. A. Te Dorsthorst, Paul E. Verweij, Jacques F. Meis, Nieko Punt, Johan W. Mouton	28
20	Routine Use of a Commercial Test, GLABRATA RTT, for Rapid Identification of Candida glabrata in Six Laboratories 2004 ·Journal of Clinical Microbiology ·A. M. Freydière, John D. Perry, O. Faure, Birgit Willinger, Anna Maria Tortorano, A. Nicholson, Javier Pemán, Paul E. Verweij	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact